CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BRAINSTORM CELL THERAPEUTICS INC.

BCLI
$8M
Micro Cap
NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEW YORK23 employees

Drugs in Pipeline

5

Phase 3 Programs

1

Upcoming Catalysts

0

Next Catalyst

None scheduled

Market Overview

Stock performance and key metrics

BCLI News
Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

How BCLI's past catalysts played out

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in BRAINSTORM CELL THERAPEUTICS INC.'s drug pipeline?

CatalystAlert tracks 5 drug candidates in BRAINSTORM CELL THERAPEUTICS INC.'s (BCLI) pipeline across Phase 3, Phase 2. Its lead program is NurOwn® (MSC-NTF cells) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is BRAINSTORM CELL THERAPEUTICS INC.'s next FDA catalyst?

CatalystAlert tracks every upcoming catalyst for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.

How do I track BCLI biotech catalysts?

Add BCLI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRAINSTORM CELL THERAPEUTICS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply